6月13日，赛诺菲中国宣布，公司针对2025-2026年流感季的四价流感病毒裂解疫苗已获得国家药品监督 管理局批签发放行。(第一财经) ...

Sanofi (NASDAQ:SNY) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care Conference Call Participants James Patrick Quigley - Goldman Sachs Group, Inc., Research Division James Patrick Quigley Excellent. So welcome, everybody. I'm James Quigley from Goldman Sachs. I'm the European pharma analyst, and it's a pleasure to welcome you all to this session with Sanofi. We're joined today by the Head of Special ...

The Food and Drug Administration on Monday approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca.The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck said in a release that it expects orders for the shot to begin in J ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 30, 2025, Sanofi issued a pres ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, 2025, Sanofi ...

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the program. Today, nearly ...

Key Takeaways Sanofi's rilzabrutinib receives FDA orphan drug designation for SCD, its fourth such indication. Preclinical data show rilzabrutinib reduced vaso-occlusion and inflammation in SCD mouse models. Rilzabrutinib is also under FDA review for ITP, with a decision expected by August 29, 2025.Sanofi (SNY) announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for sickle cell disease (SCD). The candidate exerts its effects through multi-immune ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse® on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently approved lines of treatment P ...

赛诺菲(SNY.US)近日宣布拟以91亿美元收购Blueprint Medicines(BPMC.US)，高盛对此表示，这笔交易 旨在通过整合Blueprint的罕见病与免疫学管线资产，帮助赛诺菲填补其核心产品Dupixent在2031/32年专 利到期后的利润缺口。因此，该行维持赛诺菲"中性"评级，目标价117欧元(ADR67美元)。 高盛在一份报告中指出，根据条款，赛诺菲将以每股129美元的现金(较5月30日收盘价溢价27%)收购 Blueprint，预付金额达91亿美元。若Blueprint的免疫学候选药物BLU-808研发成功，股东还可获得两项 每股2美元和4美元的额外或有价值权(CVR)，总交易额最高可达95亿美元。此次交易预计将于2025年第 三季度完成。 本次收购的核心资产包括已获批的酪氨酸激酶抑制剂Ayvakit(用于治疗肥大细胞相关罕见病)及在研药物 BLU-808(针对非突变KIT，适应症为慢性荨麻疹、过敏性哮喘等免疫疾病)等。据Visible Alpha预测， Ayvakit的2033年峰值销售额可达23.5亿欧元(毛利率高达95%);BLU-808的2033年峰值销售额预期可达27 亿 ...

Key Takeaways Sanofi will acquire BPMC for up to $9.5B, including a 27% premium and CVRs tied to BLU-808 milestones. The deal adds Ayvakit, which saw Q1 2025 sales of $149.4M and is projected to hit $2B by 2030. SNY aims to reduce Dupixent reliance by expanding its immunology portfolio through acquisitions.Sanofi (SNY) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC) for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are ...